Lee J. Helman

23.2k citations

208 papers · 14.3k indexed · 2 hit papers · h-index 67

Impact in

Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
Pulmonary and Respiratory Medicine top 0.2%
- Sarcoma Diagnosis and Treatment

Papers in

Cancer Research 38
- Cancer, Hypoxia, and Metabolism 23
Pulmonary and Respiratory Medicine 82
- Sarcoma Diagnosis and Treatment 76

Co-authors: Xiaolin Wan Chand Khanna Paul S. Meltzer Arnulfo Mendoza Choh Yeung Patrick J. Grohar Glenn Merlino Thea Kalebic
Journals: Journal of Clinical Oncology (24 papers)Cancer Research (16 papers)Clinical Cancer Research (12 papers)Journal of Biological Chemistry (9 papers)Oncogene (8 papers)
Partner nations: United States Italy United Kingdom

In The Last Decade

Lee J. Helman

207 papers receiving 14.1k citations

Hit Papers

align trajectories log scale

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism 2006 · 630 citations

Peers

Countries citing papers authored by Lee J. Helman

Since Specialization

Citations

This map shows the geographic impact of Lee J. Helman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee J. Helman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee J. Helman more than expected).

Fields of papers citing papers by Lee J. Helman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee J. Helman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee J. Helman. The network helps show where Lee J. Helman may publish in the future.

Co-authors

The 25 scholars most cited alongside Lee J. Helman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lee J. Helman Line = papers co-authored together Lee J. Helman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma Molecular Cancer Therapeutics ·Guillermo Flores, Joel H. Everett, Elissa A. Boguslawski, Brandon M. Oswald, Zachary Madaj, Ian Beddows, Sergey Dikalov, Marie Adams, Carleen Klumpp‐Thomas, Susan M. Kitchen-Goosen, Scott E. Martin, Natasha J. Caplen, Lee J. Helman, Patrick J. Grohar	2020	17
2	Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma Cancer Research ·Katherine K. Slemmons, Choh Yeung, Joshua T. Baumgart, Jhazeel O. Martinez Juarez, Amy McCalla, Lee J. Helman	2020	22
3	EWS-FLI1–regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth Molecular Cancer Therapeutics ·Sameer H. Issaq, Arnulfo Mendoza, Ria Kidner, Tracy I. Rosales, Damien Duveau, Christine M. Heske, Jason M. Rohde, Matthew B. Boxer, Craig J. Thomas, Ralph J. DeBerardinis, Lee J. Helman	2020	25
4	Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma Clinical Cancer Research ·Christine M. Heske, Mindy I. Davis, Joshua T. Baumgart, Kelli M. Wilson, Michael V. Gormally, Lu Chen, Xiaohu Zhang, Michele Ceribelli, Damien Duveau, Rajarshi Guha, Marc Ferrer, Fernanda I. Arnaldez, Jiuping Ji, Huong-Lan Tran, Yiping Zhang, Arnulfo Mendoza, Lee J. Helman, Craig J. Thomas	2017	50
5	Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor Clinical Cancer Research ·Christy Osgood, Nichole Maloney, Christopher G. Kidd, Susan M. Kitchen-Goosen, Laura Segars, Meti Gebregiorgis, Girma M. Woldemichael, Min He, Savita Sankar, Stephen L. Lessnick, Min H. Kang, Malcolm A. Smith, Lisa Turner, Zachary Madaj, Mary E. Winn, Luz-Elena Núñez, Javier González‐Sabín, Lee J. Helman, Francisco Morís, Patrick J. Grohar	2016	57
6	SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma Clinical Cancer Research ·Sai-Wen Tang, Sven Bilke, Liang Cao, Junko Murai, Fabrício G. Sousa, Mihoko Yamade, Vinodh N. Rajapakse, Sudhir Varma, Lee J. Helman, Javed Khan, Paul S. Meltzer, Yves Pommier	2015	70
7	Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth Clinical Cancer Research ·Patrick J. Grohar, Laure E. Segars, Choh Yeung, Yves Pommier, Maurizio D’Incalci, Arnulfo Mendoza, Lee J. Helman	2013	60
8	Cediranib for Metastatic Alveolar Soft Part Sarcoma Journal of Clinical Oncology ·Shivaani Kummar, Deborah Allen, Anne Monks, Eric C. Polley, Curtis Hose, S. Percy Ivy, Barış Türkbey, Scott M. Lawrence, Robert J. Kinders, Peter L. Choyke, Richard Simon, Seth M. Steinberg, James H. Doroshow, Lee J. Helman	2013	156
9	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study Journal of Clinical Oncology ·Alberto S. Pappo, Shreyaskumar Patel, John Crowley, Denise K. Reinke, Klaus-Peter Kuenkele, Sant P. Chawla, Guy C. Toner, Robert G. Maki, Paul A. Meyers, Rashmi Chugh, Kristen N. Ganjoo, Scott M. Schuetze, Heribert Juergens, Michael Leahy, Birgit Geoerger, Robert S. Benjamin, Lee J. Helman, Laurence H. Baker	2011	252
10	Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer Cancer Research ·Liang Cao, Yunkai Yu, Sven Bilke, Robert L. Walker, Linnia H. Mayeenuddin, David O. Azorsa, Fan Yang, Marbin Pineda, Lee J. Helman, Paul S. Meltzer	2010	174
11	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas Clinical Cancer Research ·Crystal L. Mackall, Eunice H. Rhee, Elizabeth J. Read, Hanh Khuu, Susan F. Leitman, Donna Bernstein, Merertu Tesso, Lauren Long, David J. Grindler, Margret Merino, William Kopp, Maria Tsokos, Jay A. Berzofsky, Lee J. Helman	2008	127
12	The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors Cancer Research ·Fei Huang, Ann Greer, Warren Hurlburt, Xia Han, Rameh Hafezi, Gayle Wittenberg, Karen A. Reeves, Jiwen Chen, Douglas Robinson, Aixin Li, Francis Y. Lee, Marco M. Gottardis, Edwin Clark, Lee J. Helman, Ricardo M. Attar, Ashok Dongre, Joan M. Carboni	2008	137
13	Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody Cancer Research ·Liang Cao, Yunkai Yu, Isaac Darko, Duane Currier, Linnia H. Mayeenuddin, Xiaolin Wan, Chand Khanna, Lee J. Helman	2008	122
14	Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival Cancer Research ·Emanuel F. Petricoin, Virginia Espina, Robyn P. Araujo, Brieanne Midura, Choh Yeung, Xiaolin Wan, Gabriel S. Eichler, Donald J. Johann, Stephen J. Qualman, Maria Tsokos, Kartik Krishnan, Lee J. Helman, Lance A. Liotta	2007	196
15	Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy Cancer Research ·Tsz‐Kwong Man, Murali Chintagumpala, Jaya Visvanathan, Jianhe Shen, László Perlaky, John Hicks, Mark E. Johnson, Nelson Davino, Jeffrey C. Murray, Lee J. Helman, William H. Meyer, Timothy J. Triche, Kwong‐Kwok Wong, Ching C. Lau	2005	107
16	Metastasis-associated differences in gene expression in a murine model of osteosarcoma. PubMed ·Chand Khanna, Javed Khan, Phoungmai Nguyen, Jennifer Prehn, Jana Caylor, Choh Yeung, Jane B. Trepel, Paul S. Meltzer, Lee J. Helman	2001	229
17	Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor. Endocrinology ·Vicky A. Blakesley, Thea Kalebic, Lee J. Helman, Bethel Stannard, Teresa N. Faria, Charles T. Roberts, Derek LeRoith	1996	55
18	In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. PubMed ·Thea Kalebic, M Tsokos, Lee J. Helman	1994	151
19	Insulin-like growth factor II-mediated proliferation of human neuroblastoma. Journal of Clinical Investigation ·Osama M. El‐Badry, Lee J. Helman, Jane Chatten, Seth M. Steinberg, A. Evans, Mark A. Israel	1991	114
20	Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. PubMed ·Daniel D. Von Hoff, Marcel Rozencweig, William T. Soper, Lee J. Helman, John S. Penta, Hugh L. Davis, Franco M. Muggia	1977	13

About Lee J. Helman

Lee J. Helman is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Neurology, Endocrinology, Diabetes and Metabolism and Oncology, having authored 208 papers that have together received 14.3k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (76 papers), Growth Hormone and Insulin-like Growth Factors (33 papers), Cancer, Hypoxia, and Metabolism (23 papers), Neuroblastoma Research and Treatments (23 papers), Neurofibromatosis and Schwannoma Cases (14 papers), Metabolism, Diabetes, and Cancer (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and CAR-T cell therapy research (12 papers). The work is most often cited by research in Cancer Research (2.4k citations), Pulmonary and Respiratory Medicine (5.0k citations), Oncology (4.0k citations), Neurology (1.7k citations) and Gastroenterology (614 citations). Lee J. Helman has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Xiaolin Wan, Chand Khanna, Paul S. Meltzer, Arnulfo Mendoza, Choh Yeung, Patrick J. Grohar, Glenn Merlino, Thea Kalebic, Mark A. Israel and Javed Khan. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Journal of Biological Chemistry and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact